ESR1 and nasopharyngeal carcinoma: Additionally, its inhibition of SRC and ESR1 could mitigate epithelial-mesenchymal transition (EMT) and hormone receptor-mediated growth, both of which are often exploited in metastatic NPC (Lasagna et al., 2020; Loo et al., 2022).